Form 4: KalVista Pharmaceuticals Chief Medical Officer Reports Stock Transactions

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, executed stock transactions involving the vesting of restricted stock units and performance stock units, followed by a sale of shares to cover tax obligations.

Summary

• Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, engaged in transactions involving the company's stock.
• On November 17, 2024, Audhya acquired 18,531 shares through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
• These RSUs and PSUs represent a contingent right to receive one share of common stock upon settlement.
• Following the vesting, on November 18, 2024, Audhya sold 8,077 shares at a weighted average price of $9.2566 per share.
• The sale was to cover tax withholding obligations related to the vesting of the RSUs and PSUs and was not a discretionary transaction.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It does not indicate any positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transactions reported are typical for executives who receive stock-based compensation, such as RSUs and PSUs.
• The 'sell to cover' mechanism is a common method for handling tax obligations related to vesting of equity awards.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve a small number of shares relative to the total outstanding shares.
• The transactions are part of the executive's compensation package and do not indicate any change in the company's performance or outlook.

Key Dates

Keywords

KalVista Pharmaceuticals, stock transactions, Form 4, insider trading, restricted stock units, performance stock units, tax withholding, Paul K. Audhya, Chief Medical Officer